Gainers
- Virpax Pharmaceuticals VRPX stock rose 12.3% to $0.34 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 million.
- Talphera TLPH stock moved upwards by 9.83% to $1.34. The company's market cap stands at $22.7 million.
- Brainstorm Cell BCLI shares rose 9.0% to $0.34. The company's market cap stands at $16.6 million.
- NKGen Biotech NKGN shares moved upwards by 8.36% to $1.03. The market value of their outstanding shares is at $22.5 million.
- 180 Life Sciences ATNF stock moved upwards by 7.63% to $0.21. The company's market cap stands at $2.0 million.
- ENDRA Life Sciences NDRA stock moved upwards by 7.14% to $1.2. The market value of their outstanding shares is at $13.2 million.
Losers
- Synaptogenix SNPX shares declined by 19.6% to $0.21 during Wednesday's after-market session. The market value of their outstanding shares is at $4.2 million.
- Portage Biotech PRTG shares decreased by 7.81% to $0.39. The market value of their outstanding shares is at $7.7 million.
- Bright Green BGXX shares fell 7.59% to $0.19. The market value of their outstanding shares is at $34.9 million.
- Motus GI Hldgs MOTS shares decreased by 7.28% to $1.02. The company's market cap stands at $1.5 million.
- Fresh2 Group FRES stock declined by 6.98% to $0.4. The company's market cap stands at $9.4 million.
- Biofrontera BFRI shares declined by 6.86% to $0.91. The company's market cap stands at $1.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ATNF180 Life Sciences Corp
$6.98-8.28%
Edge Rankings
Momentum
99.42
Price Trend
Short
Medium
Long
BCLIBrainstorm Cell Therapeutics Inc
$0.6035-48.4%
BFRIBiofrontera Inc
$0.9500-1.66%
BGXXBright Green Corp
$0.0380-74.3%
MOTSMotus GI Holdings Inc
$0.0785-54.8%
NDRAENDRA Life Sciences Inc
$4.572.93%
NKGNNKGen Biotech Inc
$0.1400-%
PRTGPortage Biotech Inc
$8.901.14%
TLPHTalphera Inc
$0.4250-1.07%
VRPXVirpax Pharmaceuticals Inc
$0.2460-63.3%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.